- Home
- EONR vs TSBX Comparison
EONR vs TSBX Comparison
Compare EONR & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- TSBX
- Stock Information
- Founded
- EONR 2017
- TSBX 2015
- Country
- EONR United States
- TSBX United States
- Employees
- EONR N/A
- TSBX N/A
- Industry
- EONR
- TSBX
- Sector
- EONR
- TSBX
- Exchange
- EONR NYSE
- TSBX Nasdaq
- Market Cap
- EONR 6.8M
- TSBX 7.7M
- IPO Year
- EONR N/A
- TSBX 2023
- Fundamental
- Price
- EONR $0.38
- TSBX $0.37
- Analyst Decision
- EONR Strong Buy
- TSBX Buy
- Analyst Count
- EONR 1
- TSBX 3
- Target Price
- EONR $2.00
- TSBX $4.75
- AVG Volume (30 Days)
- EONR 14.9M
- TSBX 459.6K
- Earning Date
- EONR 08-15-2025
- TSBX 08-13-2025
- Dividend Yield
- EONR N/A
- TSBX N/A
- EPS Growth
- EONR N/A
- TSBX N/A
- EPS
- EONR N/A
- TSBX N/A
- Revenue
- EONR $19,638,616.00
- TSBX N/A
- Revenue This Year
- EONR $46.94
- TSBX N/A
- Revenue Next Year
- EONR $64.38
- TSBX N/A
- P/E Ratio
- EONR N/A
- TSBX N/A
- Revenue Growth
- EONR N/A
- TSBX N/A
- 52 Week Low
- EONR $0.33
- TSBX $0.29
- 52 Week High
- EONR $2.92
- TSBX $2.69
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- TSBX 54.35
- Support Level
- EONR N/A
- TSBX $0.33
- Resistance Level
- EONR N/A
- TSBX $0.37
- Average True Range (ATR)
- EONR 0.00
- TSBX 0.02
- MACD
- EONR 0.00
- TSBX 0.00
- Stochastic Oscillator
- EONR 0.00
- TSBX 64.17
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.